A 32-year-old man with treatment-resistant schizophrenia has failed adequate trials of risperidone, olanzapine, and aripiprazole. The PMHNP is considering initiating clozapine. The patient's baseline ANC is 2,100/mcL and he has no history of blood dyscrasias. During the informed consent discussion, the patient asks about the monitoring requirements. Which of the following accurately describes the REMS monitoring schedule for clozapine?